A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of BJT-778 in Subjects with Chronic HBV Infection (CHB) and Chronic HDV Infection (CHD).
A Phase 1/2a, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of BJT-778 in Healthy Volunteers and in Subjects with Chronic Hepatitis B Infection, Including Subjects with Chronic Hepatitis D Infection - Part 3 conducted in individuals with chronic hepatitis B and D co-infection.
Bluejay Therapeutics Inc.
72 participants
May 20, 2023
Interventional
Conditions
Summary
Hepatitis B virus (HBV) infection is one of the most common infectious diseases in the world, with nearly 300 million people chronically infected worldwide. Chronic HBV infection can lead to serious complications such as cirrhosis, liver failure, hepatocellular carcinoma (HCC), and death. Approximately 820,000 people die every year due to consequences of CHB. Hepatitis delta virus (HDV) is the causative agent of chronic hepatitis delta (CHD), the most severe form of viral hepatitis. Infection with HDV is dependent on the presence of HBV infection, as it uses HBV encoded envelope proteins (HBsAg) for infection and replication HDV infection can occur either simultaneously with HBV or, more commonly, as a superinfection in patients already chronically infected with HBV. Relative to CHB infection alone, CHD co-infection is associated with more severe liver disease, causing faster progression to cirrhosis, hepatocellular carcinoma, and liver failure. Developing therapeutic strategies that deplete HBsAg levels, like monoclonal antibodies, may play a role in future regimens targeting functional cure. There is a clear need for additional treatment for CHD, particularly agents that improve response rates, are better tolerated, and simpler to administer than currently available treatments. BlueJay Therapeutics has developed BJT-778, which has the potential to provide anti HBV and anti HDV benefits by neutralizing and clearing HBV and HDV virions as well as by depleting HBsAg containing subviral particles, which may help reconstitute HBV-specific immunity and contribute to functional cure for CHB. BJT-778 is a potent, selective neutralizing monoclonal antibody for the treatment of CHB and CHD. This study will evaluate the safety, tolerability, pharmacokinetics and antiviral activity of BJT-778 in participants with Chronic HBV Infection (CHB) and Chronic HDV Infection (CHD).
Eligibility
Plain Language Summary
Simplified for easier understanding
This is a simplified summary. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
BJT-778 is being developed as a potent, selective neutralizing monoclonal antibody for the treatment of Chronic Hepatitis B Virus Infection (CHB) and Chronic Hepatitis D Virus Infection (CHD). Cohort D: Dosing of Groups D1 (Dose 1) may initiate when the Dose 1 is deemed safe in healthy volunteers (Group A1) by the Safety Review Committee (SRC) at the Day 14 safety review. Dose escalation to Dose 2 (Group D2) may proceed when the Day 14 safety review of the healthy volunteers at the Dose 2 (Group A2) and the Dose 1 in HBV-infected subjects (all participants from B1, and enrolled participants from D1) have determined to have acceptable safety profiles. The SRC will also incorporate available longer-term safety, efficacy, and PK data from all current and prior dosing groups into the decision making. Dose escalation to the optional Dose 3 in each group (B3, C3 and D3) may proceed once at least 14-day safety is established in the healthy volunteers at Dose 3 (Group A3) and 14-day safety is established at Dose 3 of the respective cohorts (B2, C2, and D2) per SRC review. Subjects will be monitored with serial vitals, ECGs, safety laboratory assessments, and AEs recording. Cohort D all will receive open-label BJT-778 and target 4 subjects per dose. Cohort D: CHB+CHD coinfection: • D1) Dose 1 ×1 subcutaneously (SC) • D2) Dose 2 ×1 SC • D3) Optional Dose 3 ×1 SC Cohort F: Once the safety and antiviral activity in Cohort D are established for a given dose (i.e., Dose 1), optional open-label multidose BJT-778 cohorts may be initiated and at different dosing intervals (i.e., every1, 2 or 4 weeks). The decision to initiate multidose cohorts for a given dose (i.e., Dose 1) will be determined by safety and maximum HDV RNA reductions observed with a single dose. Approximately 10 subject per cohort, this may be expanded to 20 subjects per cohort will be enrolled in Cohort F. For a given dose (i.e., Dose 1), cohorts exploring different intervals may enroll simultaneously or sequentially at the discretion of the Sponsor. • F1) Optional Dose considered safe in Cohort D, given subcutaneously at a TBD interval for 12 weeks • F2) Optional Dose considered safe in Cohort D, given subcutaneously at a TBD interval for 12 weeks • F3) 900mg SC at week 0, 2 and 4, then every 4 weeks up to week 48 All Subjects will continue their nucleos(t)ide treatment for the duration of the study including the follow up. Doses fall within the range of 75mg to 900mg and the exact doses will be disclosed after IP restrictions are met.
Locations(9)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12623000105640